

Cytokine levels in vitreous, aqueous, and plasma

Vitreous cytokine	Control (pg/mL) (95% CI) n=7	Diabetic (pg/mL) (95% CI) n=17	p-value
IL-6	1.79 (1.13, 2.45)	115 (-26.1, 255)	0.0003*
IL-8	15.3 (-0.631, 31.2)	208 (61.6, 354)	0.00048*
TNF- α	0.046 (0.0207, 0.0712)	0.219 (0.121, 0.317)	0.00108*
MCP-1	825 (577, 1073)	3225 (2145, 4305)	0.0131*
MIP-1 β	11.5 (7.56, 15.5)	29.7 (21.4, 37.9)	0.0220*
Flt-1	6252 (3969, 8536)	9183 (6853, 11513)	0.184
PIGF	1.13 (0.434, 1.83)	103 (13.0, 193)	0.00048*
VEGF-A	2.61 (-0.730, 5.94)	1799 (-77.9, 3676)	0.00148*
VEGF-C	65.3 (14.0, 116)	382 (51.9, 712)	0.327
VEGF-D	45.9 (-26.4, 118)	123 (42.6, 203)	0.0703

Aqueous cytokine	Control (pg/mL) (95% CI) n=7	Diabetic (pg/mL) (95% CI) n=17	p-value
IL-6	2.12 (-0.127, 4.36)	137 (-68.7, 342)	0.0035*
IL-8	9.55 (5.28, 13.8)	68.0 (29.6, 106)	0.00096*
TNF- α	0.02 (0.02, 0.02)	1.03 (-0.0587, 2.11)	0.194
MCP-1	7458 (2691, 12225)	22867 (5082, 40652)	0.749
MIP-1 β	77.2 (33.3, 121)	149 (103, 195)	0.0561
Flt-1	550 (370, 729)	1643 (-37.3, 3323)	0.569
PIGF	1.34 (0.405, 2.28)	20.5 (10.7, 30.3)	0.0003*
VEGF-A	208 (147, 270)	656 (265, 1046)	0.342
VEGF-C	9.85 (3.42, 16.3)	74.6 (-7.30, 157)	0.0131*
VEGF-D	23.6 (1.96, 45.2)	45.0 (16.6, 73.5)	0.522

Plasma cytokine	Control (pg/mL) (95% CI) n=7	Diabetic (pg/mL) (95% CI) n=17	p-value
IL-6	0.974 (0.54, 1.40)	1.12 (0.568, 1.66)	0.826
IL-8	5.51 (3.99, 7.03)	34.8 (-22.7, 92.2)	0.897
TNF- α	1.77 (1.38, 2.16)	3.01 (2.09, 3.92)	0.0751
MCP-1	215 (124, 305)	270 (179, 360)	0.749
MIP-1 β	174 (89.7, 259)	158 (112, 204)	0.952
Flt-1	109 (59.4, 160)	107 (79.3, 135)	0.803
PIGF	5.14 (2.61, 7.67)	8.85 (5.77, 11.9)	0.112
VEGF-A	141 (-31.8, 315)	168 (74.6, 262)	0.373
VEGF-C	135 (51.3, 219)	140 (102, 178)	0.704
VEGF-D	1377 (1006, 1748)	2434 (1757, 3111)	0.0751

* = statistically significant at $p < 0.05$

Supplementary Table S1: Identification of cytokine differences in vitreous, aqueous, and plasma from diabetic patients versus controls. Vitreous IL-6, IL-8, TNF- α , MCP-1, MIP-1 β , PIGF, and VEGF-A and aqueous IL-6, IL-8, PIGF, and VEGF-C were elevated in diabetic patients compared to controls. There was no significant

difference in plasma level of any factors between the two groups. Diabetic group includes those with and without recent anti-VEGF injection. *P < 0.05